Finance
Markets
No recent trading data. The last price we hold for INCY is from Jun 3 (48 days ago). This symbol may be delisted, renamed, or halted — the figures below reflect its last active session, not the current market.

INCY

stock Healthcare Biotechnology
Incyte
$97.98 +5.74 (+6.22%) Delayed · quoted 47d ago
Healthy 80% Climbing

What the indicators say

Bullish 5 of 5 trend signals bullish
Momentum · RSI 14 Neutral
54
0oversold 30overbought 70100

RSI 54 — momentum is balanced between buyers and sellers.

EMA 21 $96.65
Above
Near-term trend is up
SMA 50 $96.09
Above
Medium-term trend is up
SMA 200 $95.84
Above
Long-term trend is up
50 / 200-day
Golden cross
50-day above the 200-day — bullish
Supertrend $91.80
Uptrend
Price is holding above the Supertrend band — bullish

A mechanical reading of the chart’s indicators — not investment advice.

Key statsas of Jun 3

The day open and close within the day's range
Low $92.66 High $98.48
Open
$97.98
+6.22%
Close
$97.98
+6.22%
52-week range where the price sits across its year
52w low $64.72 52w high $112.29
Current
$97.98
Prev close
$92.24
Volume 1.49× the 3-month average
0 avg 2× avg
Today
2.19M
3-mo avg
1.47M

Earningscalendar synced from Yahoo 57d ago

Most recent
Apr 2884 days ago
Next expected
Jul 28in 7 days

Recent earnings dates

  • Apr 28 84 days ago
  • Feb 10 161 days ago
  • Oct 28, 2025 266 days ago
  • Jul 29, 2025 357 days ago

Past earnings dates come from INCY’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.

Fundamentalssynced from SEC 51d ago

Strong

Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), INCY’s fundamentals read as strong overall.

P/E ratio Strong
13.8x

At 13.8x, the price is a reasonable multiple of the company's annual profit.

Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.

Dividend yield Fair
0.00%

This company pays no dividend, common for firms reinvesting their profits back into growth.

The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.

Profit margin Strong
25.0%

A 25.0% margin is strong; the company keeps a healthy slice of every revenue dollar.

The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.

Return on equity Strong
24.9%

A 24.9% return on equity is strong; the company compounds owners' capital well.

Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.

Return on assets Strong
18.5%

A 18.5% return on assets is strong; the company squeezes good profit from its assets.

Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.

Debt-to-equity Strong
0.35

At 0.35, the company carries less in liabilities than in equity, a conservative balance sheet.

Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.

Current ratio Strong
3.32

At 3.32, short-term assets comfortably cover short-term bills.

Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.

Revenue growth Strong
+21.2%

Revenue grew 21.2% from the prior year: strong top-line expansion.

Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.

Earnings growth Strong
+3845.0%

Net income grew 3845.0% from the prior year: strong profit expansion.

Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.

Financialssynced from SEC 51d ago

FY2021FY2022FY2023FY2024FY2025
Revenue $3.0B$3.4B$3.7B$4.2B$5.1B
Net income $948.6M$340.7M$597.6M$32.6M$1.3B
Diluted EPS $4.27$1.52$2.65$0.15$6.41
Dividend / share
Total assets $4.9B$5.8B$6.8B$5.4B$7.0B
Total liabilities $1.2B$1.5B$1.6B$2.0B$1.8B
Shareholder equity $3.8B$4.4B$5.2B$3.4B$5.2B

Leadershipsynced from SEC 56d ago

  • Meury William Chief Executive Officer · Director
  • Upadhyay Suketu EVP & Chief Financial Officer
  • Cagnoni Pablo J President, Global Head of R&D
  • Stein Steven H CMO & Head of Late-Stage Dev.
  • 667, L.p. Director
  • Baker Bros. Advisors (gp) Llc Director
  • Baker Bros. Advisors Lp Director
  • Baker Brothers Life Sciences Lp Director
  • Baker Felix Director
  • Baker Julian Director
  • Clancy Paul J Director

Officers and board are drawn from INCY’s recent SEC ownership filings (Forms 3, 4 and 5).

Notable recent eventspast year

Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.

Recent SEC filingssynced from SEC 51d ago